Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.38 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.34 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.34 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30012981 | 1.00 | AAK1 (0.38) | AAK1S1PR1S1PR3SSTR4GAA | |
| SCHEMBL22026488 | 0.83 | MET (0.33) | SSTR4GAA | |
| SCHEMBL31065386 | 0.75 | SCN5A (0.39) | S1PR1S1PR3GAASMN1; SMN2POLB | |
| SCHEMBL27150293 | 0.75 | HCAR2 (0.37) | — | |
| SCHEMBL17316585 | 0.75 | AAK1 (0.47) | AAK1S1PR1S1PR3SSTR4 | |
| SCHEMBL26464229 | 0.74 | AAK1 (0.50) | AAK1S1PR1S1PR3SSTR4 | |
| SCHEMBL27150846 | 0.73 | ATM (0.42) | GAA | |
| SCHEMBL9949151 | 0.72 | AAK1 (0.40) | AAK1S1PR1S1PR3SMN1; SMN2 | |
| SCHEMBL323430 | 0.72 | AAK1 (0.38) | AAK1S1PR1S1PR3SMN1; SMN2POLB | |
| SCHEMBL22770846 | 0.71 | S1PR1 (0.36) | AAK1S1PR1S1PR3SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240199587-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2024-06-20 | — | — | US | disclosed |
| EP-4326714-A1 | HETEROCYCLIC COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2024-02-28 | — | — | EP | disclosed |
| CN-117295726-A | Heterocyclic compounds | 豪夫迈·罗氏有限公司 | 2023-12-26 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240199587-A1 | HETEROCYCLIC COMPOUNDS | CYP1B1, CYP1A1, CYP4B1 | AAK1 3660/4885S1PR1 3844/4885S1PR3 3654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.